This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The University of California, Davis (UC Davis) is proposing to create a Clinical and Translational Science Center (CISC) which will transform our medical research enterprise into a highly jeffective """"""""open"""""""" academic home for clinical and translational research by building on three key assets: 1) Our long-standing commitment as a land-grant university to serve the geographically disperse and ethnically diverse populations of inland and Northern California with a health care system enabled by one of the broadest and most extensive telecommunications programs in the world;2) The collaborative culture of UC Davis, which has one of the most extensive and interdisciplinary life science environments in the country, and 3) An established CSTC pilot facility - the UC Davis Clinical Research Investigator Services Program (CRISP) that serves as the physical home for clinical and translational research and for faculty training and career development. CRISP is a fundamentally important CTSC testing ground, where many perceived CTSA barriers have been explored and solutions tested, and through CRISP, we have completed the planning phase for the CTSC. In the organizational structure of the UC Davis CTSC, considerable attention is paid to create an organization that is: 1) responsive and familiar to investigators;2) flexible;3) well linked to university leadership, to participating academic units, and to the community;and 4) focused on the goal of reducing barriers and facilitating the translation of research gains into medical practice. Key features are: Education program focused on """"""""team science"""""""";Extensive collaborations across UC Davis colleges and centers;Introduction of catalyst functions such as Collaborative Research Facilitators and translational postdoctoral fellowships;Dissemination through tele-technology;Flexible use of resources for patientoriented research;and a Community engagement program emphasizing trust and respect. The CTSC is under the leadership of two co-Principal Investigators, Drs. Berglund MD, PhD, (P.I.) and Joseph MD, PhD (co-P.I.), supported by a team of Directors and co-Directors overseeing each of the 9 CTSC programs, and a comprehensive committee structure, designed to firmly anchor the CTSC with institutional leadership, faculty, trainees and the community. The UC Davis CTSC will be implemented through a carefully designed, collaborative plan, and the activity will be guided through continuous evaluations and corrections.

Agency
National Institute of Health (NIH)
Institute
National Center for Research Resources (NCRR)
Type
Linked Specialized Center Cooperative Agreement (UL1)
Project #
5UL1RR024146-04
Application #
7961446
Study Section
Special Emphasis Panel (ZRR1-CR-A (01))
Project Start
2009-07-01
Project End
2010-06-30
Budget Start
2009-07-01
Budget End
2010-06-30
Support Year
4
Fiscal Year
2009
Total Cost
$1,907,462
Indirect Cost
Name
University of California Davis
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
047120084
City
Davis
State
CA
Country
United States
Zip Code
95618
Lane, Nancy E; Mohan, Geetha; Yao, Wei et al. (2018) Prevalence of glucocorticoid induced osteonecrosis in the mouse is not affected by treatments that maintain bone vascularity. Bone Rep 9:181-187
Oskarsson, Björn; Moore, Dan; Mozaffar, Tahseen et al. (2018) Mexiletine for muscle cramps in amyotrophic lateral sclerosis: A randomized, double-blind crossover trial. Muscle Nerve :
Sparger, Ellen E; Murphy, Brian G; Kamal, Farina Mustaffa et al. (2018) Investigation of immune cell markers in feline oral squamous cell carcinoma. Vet Immunol Immunopathol 202:52-62
Minzenberg, Michael J; Yoon, Jong H; Soosman, Steffan K et al. (2018) Altered brainstem responses to modafinil in schizophrenia: implications for adjunctive treatment of cognition. Transl Psychiatry 8:58
Gingrich, Alicia A; Elias, Alexandra; Michael Lee, Chia-Yuan et al. (2017) Predictors of residual disease after unplanned excision of soft tissue sarcomas. J Surg Res 208:26-32
Palmieri, Tina L; Holmes 4th, James H; Arnoldo, Brett et al. (2017) Transfusion Requirement in Burn Care Evaluation (TRIBE): A Multicenter Randomized Prospective Trial of Blood Transfusion in Major Burn Injury. Ann Surg 266:595-602
Li, Tianhong; Piperdi, Bilal; Walsh, William V et al. (2017) Randomized Phase 2 Trial of Pharmacodynamic Separation of Pemetrexed and Intercalated Erlotinib Versus Pemetrexed Alone for Advanced Nonsquamous, Non-small-cell Lung Cancer. Clin Lung Cancer 18:60-67
López-Yoldi, Miguel; Stanhope, Kimber L; Garaulet, Marta et al. (2017) Role of cardiotrophin-1 in the regulation of metabolic circadian rhythms and adipose core clock genes in mice and characterization of 24-h circulating CT-1 profiles in normal-weight and overweight/obese subjects. FASEB J 31:1639-1649
Fleischman, Ross J; Mann, N Clay; Dai, Mengtao et al. (2017) Validating the Use of ICD-9 Code Mapping to Generate Injury Severity Scores. J Trauma Nurs 24:4-14
Taylor, Sandra L; Sen, Soman; Greenhalgh, David G et al. (2016) Real-Time Prediction for Burn Length of Stay Via Median Residual Hospital Length of Stay Methodology. J Burn Care Res 37:e476-82

Showing the most recent 10 out of 530 publications